FDA Approves Ionis' Zilganersen for Rare Alexander Disease
IONS sits 16% above its 52-week low of $50.005.
Summary
The FDA approved Ionis' therapy zilganersen for Alexander disease, a rare genetic disorder affecting the brain's white matter. This is a new approval, distinct from the TRYNGOLZA approval in June for severe hypertriglyceridemia. The approval follows the June licensing deal with Recordati for zilganersen, which covers commercialization outside the U.S. Ionis now has a second approved product in 2026, adding a new revenue stream. The company reported a Q2 net loss of $114.6M, so this approval is a meaningful positive. Watch for launch details and pricing.
Updates
· SEC 8-K — Ionis received a Rare Pediatric Disease Priority Review Voucher with the approval. ZANVASTRO 50 mg is administered quarterly as an intrathecal injection and will be available in the U.S. in the coming weeks.
At the time of this announcement, IONS was trading at $58.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $50.01 to $86.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.